

29 October 2026

Q1 FY27 Quarterly Activities Report

Positive operating cash flow of \$0.9m

Melbourne, Australia - [Atomos Limited](#) (ASX:AMS) ('**Atomos**' or the '**Company**') today releases its Appendix 4C and Quarterly Activities Report for the three-month period ended 30 September 2026 (Q1'27), along with an update on notable events that have occurred subsequently.


Highlights

- Net cash from operating activities of \$0.9m for Q1'27, with customer receipts of \$10.8m as the elevated June 2026 debtor balance was collected
- Q1'27 sales of \$9.2m, driven by continued demand for Shinobi II and positive take-up of the recently released Sumo-Pro-19; Flanders contributing in-line with expectations
- Three awards at IBC 2026 in Amsterdam: Shinobi 7 II won CineD Best of Show and the ProVideo Coalition Best Value Innovation award, and Flanders Scientific's GaiaColor AutoCal and Analyzer won TV Tech Best of Show
- New product releases anticipated in Q2'27, expected to underpin Q2 historically being one of the strongest quarters
 - Shinobi 7 II began shipping in late September, with further orders in backlog
- Cash and cash equivalents of \$2.0m at 30 September 2026

Commenting on the Q1'27 results, Atomos Managing Director and CEO, Peter Barber, said, "This quarter we delivered positive operating cash flow while continuing to transition our range. The response to Shinobi 7 II and our IBC awards show that customers value what we are building, and Flanders Scientific has had a strong first full quarter with the Group. Our priorities are converting that demand into sales, securing component supply, and building a broader Atomos and Flanders Scientific portfolio across on-camera, on-set, broadcast and finishing. Noting the typical seasonality in the business, we anticipate a strong Q2, further supported by new product launches."

Financial Update

Net cash from / (used in) operating activities (A\$m)




Quarterly figures as reported in each Appendix 4C (FY26 quarters as presented in the June 2026 Appendix 4C year to date). From the September 2026 quarter, interest paid is presented in financing activities, consistent with the Company's annual financial statements; prior quarters included interest paid in operating activities (FY26 total \$172,000). From the September 2026 quarter, capitalised research and development expenditure is presented in investing activities consistent with the Company's annual financial statements; prior quarters included research and development expenditure in operating activities (FY26 total \$1,355,000)

- Sales of \$9.2m (Q1'26: \$10.5m; Q4'26: \$9.7m) driven by strong demand for Shinobi II and Sumo PRO 19
- The Company continued to reshape its route to market, moving to direct relationships with key European resellers and new distribution partners in Australia, Japan and India
- Net operating cash inflow of \$0.9m, the second positive quarter in the last three. Increased receipts from customers of \$10.8m reflected the collection of elevated debtors as of 30 June. Fixed costs remain consistent with robust cost controls in place.
- Net investing cash outflow of \$0.8m primarily driven by capitalised development and intellectual property of \$0.7m
- Cash and cash equivalents of \$2.0m at 30 September 2026
- Borrowings of \$21.1m as of 30 September 2026
- Payments to related parties and their associates during the quarter of \$144,000, comprising directors' fees and remuneration of the executive director.

Operational Update

IBC 2026: Atomos and Flanders Scientific exhibited side by side, presenting a connected workflow from on-camera monitoring and recording through to on-set and finishing. A new combined Atomos and Flanders Scientific product catalogue was launched with new products targeted for release over the course of FY27.

Shinobi 7 II is a 7-inch, 2,800-nit HDR monitor with camera control at US\$499. Initial sales were generated in late September, however industry-wide component shortages are constraining Shinobi inventory despite customer demand. Production is being prioritised to meet orders.



Shogun AV-19M is a 19-inch rack monitor-recorder with NDI, SDI and HDMI, extending Atomos into broadcast and professional AV.

ATOMOSphere added integrations with ShotPut Studio and PlanckOne FoleyAI.

Flanders Scientific: GaiaColor AutoCal and Analyzer are now available across the DM Series, while enhanced integration with Pomfort Livegrade enables simultaneous live grading of up to four camera feeds on a single XMP or XMP C Series monitor.

Corporate Update

Board

Simon Traynor was appointed as a Non-Executive Director on 6 October 2026. Simon brings more than 25 years of executive and board experience with a particular strength in consumer marketing, retail and direct-to-consumer businesses which are particularly relevant to Atomos next phase of growth.

Jeromy Young, current Non-Executive Director, will not stand for re-election and will retire post the Company's AGM in November. Jeromy was a co-founder of Atomos and over the journey played a key role in building Atomos into the innovative global video technology business it is today.

Share Consolidation

As announced on 19 October 2026, Atomos intends to undertake a consolidation of its issued capital, whereby, subject to shareholder approval, every 20 shares will be consolidated into 1 share (**Consolidation**).

The Consolidation is intended to simplify Atomos' capital structure by reducing the number of shares on issue to a level that the Board considers more proportionate to the Company's scale and more readily comparable with relevant listed peers. It may also improve price granularity, as a higher share price reduces the minimum ASX price increment as a percentage of the share price.

The Consolidation will not alter the underlying value of shareholders' shareholdings or their proportional ownership in the Company, other than minor changes resulting from the treatment of fractional entitlements.

Outlook

Q2 has historically been the Company's strongest trading quarter. Atomos enters Q2 with new products in market, a growing order book for Shinobi 7 II, and new Flanders Scientific reference monitors to be launched.

Although, trading conditions remain subdued (driven by inflationary pressures particularly in the US market) with component supply temporarily constrained, the Company is actively implementing new sales initiatives to drive demand and diversify the revenue base. The cost base, an area the company has direct control over, is being managed tightly with inventory and working capital watched closely.

This announcement has been authorised for lodgement with ASX by the Board of Directors.

--ENDS--

For further information, please contact:

Peter Barber

Managing Director and CEO

peter@atomos.com

Atomos' Interactive Investor Hub

Our investor hub is an interactive location to engage with the Atomos team on our announcements and updates.

Please go to the Atomos Investor Hub for all market announcements & other news <https://investors.atomos.com>


About Atomos

ATOMOS designs pioneering products that transform the way film and video content is made around the world. From our range of hardware devices for monitoring and recording, easy-to-use software tools, and intelligent cloud services, we engineer best-in-class technologies and create products for the next generation of filmmakers.

Through relentless innovation, we simplify your workflow. Whether you record cinema-quality footage, monitor a scene with crystal clear colour accuracy, switch between multiple cameras, or stream a live event with a portable studio, ATOMOS empowers anyone to realize the best possible version of their creative potential.

ATOMOS is based in Melbourne, Australia, with a distributed worldwide team and offices in the USA, Japan, China, UK, and Germany and has a worldwide distribution partner network.

For more information, please visit www.atomos.com



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Atomos Limited

ABN

25 139 730 500

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities			
1.1 Receipts from customers		10,821	10,821
1.2 Payments for			
(a) research and development		(49)	(49)
(b) product manufacturing and operating costs		(5,899)	(5,899)
(c) advertising and marketing		(759)	(759)
(d) leased assets		-	-
(e) staff costs		(2,076)	(2,076)
(f) administration and corporate costs		(1,174)	(1,174)
1.3 Dividends received (see note 3)		-	-
1.4 Interest received		1	1
1.5 Interest and other costs of finance paid		-	-
1.6 Income taxes paid		(12)	(12)
1.7 Government grants and tax incentives		-	-
1.8 Other		-	-
1.9 Net cash from / (used in) operating activities		853	853
<i>Note: amounts in this section do not include GST</i>			
2. Cash flows from investing activities			
2.1 Payments to acquire or for:			
(a) entities		(70)	(70)
(b) businesses		-	-
(c) property, plant and equipment		(30)	(30)
(d) investments		-	-
(e) intellectual property		(655)	(655)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(755)	(755)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	5	5
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	- Other (AASB16 Principal Repayments)	(146)	(146)
	- Other Interest Paid*	(269)	(269)
3.10	Net cash from / (used in) financing activities	(410)	(410)

* Consistent with the classification adopted in the Company's annual financial statements, interest paid is presented within financing activities. Quarterly reports to June 2026 presented interest paid within operating activities (item 1.5).

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period*	2,324	2,324
4.2	Net cash from / (used in) operating activities (item 1.9 above)	853	853
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(755)	(755)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(410)	(410)
4.5	Effect of movement in exchange rates on cash held	(23)	(23)
4.6	Cash and cash equivalents at end of period	1,989	1,989
*Opening cash and cash equivalents has been restated from the \$2,302k reported in the June 2026 quarter to \$2,324k to include a Flanders Scientific PayPal account balance of \$22k at 30 June 2026 identified after that report was lodged.			

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,804	2,209
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (Rental Guarantees)	185	115
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,989	2,324

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	144
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
Note: From the September 2026 quarter, item 6.1 reports payments to related parties as defined in ASX Listing Rule 19.12 (s228 Corporations Act): directors of Atomos Limited and their associates and controlled entities, stated net of GST. In prior quarters this item also included remuneration of non-director key management personnel.		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	10,000	10,000
7.2	Credit standby arrangements	-	-
7.3	Other (Debt Facility*)	11,098	11,098
7.3	Other (Corporate Credit Card)	278	82
7.4	Total financing facilities	21,376	21,180
7.5	Unused financing facilities available at quarter end		196
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. * On 24 September 2025, we announced an extended \$15.7m loan facility with Monreii Pty Ltd. On 1 December 2025, we announced this facility had been repaid down to \$9.7m following the exercise of 259.8 million ASX-listed options. The facility liability stands at \$11.1m as at 30 September 2026, including all Capitalised Interest, maturity 28th February 2028. As announced here, the cost of this loan has now been reduced from 20% to 13%. In addition, the Company has received a further \$10.0m of funding from CBA in line with terms announced here. The CBA facility is a 3-year, variable-rate facility (funding cost c.10.35%), secured pari passu with the Monreii facility.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	853
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,989
8.3	Unused finance facilities available at quarter end (item 7.5)	196
8.4	Total available funding (item 8.2 + item 8.3)	2,185
8.5	Estimated quarters of funding available (item 8.4, divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: N/A 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: N/A	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29 October 2026



Authorised by: Peter Barber, CEO
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.